SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.47% Stake in Aurinia Pharmaceuticals
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have jointly filed an amended Schedule 13G, reporting a beneficial ownership of 4.47% in Aurinia Pharmaceuticals Inc. as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G.
- The filing reports their beneficial ownership in Aurinia Pharmaceuticals Inc. (the "Issuer").
- As of December 31, 2024, the Reporting Persons beneficially own 6,400,000 common shares of Aurinia Pharmaceuticals Inc.
- This ownership represents 4.47% of the Issuer's common shares outstanding.
- The percentage is calculated based on 143,179,269 shares outstanding as of November 6, 2024, as reported in the Issuer's Form 10-Q filed on November 7, 2024.
- Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these shares.
- Steven Boyd, as the managing member of Armistice Capital, LLC, also shares voting and dispositive power over the shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the Issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership, providing no positive or negative operational or financial news about the issuer.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment firm in a pharmaceutical company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that an investment firm holds a stake in a company within the pharmaceutical sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-11-06 | Date as of which 143,179,269 shares outstanding were reported in Issuer's Form 10-Q. |
| 2024-11-07 | Date Issuer's Form 10-Q was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Aurinia Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.